MedTrace Logo

Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome

NCT02156674 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2020-12-23

Study results available
· View outcomes & findings →

Summary

This is a single center study in which Naglazyme® will be given weekly for two years in patients with Maroteaux-Lamy syndrome, also known as mucopolysaccharide VI (MPS VI), who have previously been treated with an allogeneic transplant.

Conditions

  • Maroteaux-Lamy Syndrome

Interventions

DRUG

Naglazyme®

1 mg per kg of body weight administered once weekly as an intravenous infusion

Sponsors & Collaborators

Principal Investigators

  • Elizabeth Braulin, M.D. · University of Minnesota

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-26
Primary Completion
2019-12-01
Completion
2019-12-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02156674 on ClinicalTrials.gov